VISIT OUR COVID-19 HUB

Our Science
GettyImages-1208505315_790x500_1_0.png
GettyImages-1208505315_1000x450_0_0_0.jpg

VISIT OUR COVID-19 HUB

Sharing resources to stay safe and updates on our efforts we hope could bring an end to the global health crisis.

Learn More

Aiming for Equity

Our Purpose
Pfizer-Equity-Diversity_380x500.png
Pfizer-Equity-Diversity_1000x450.jpg

Aiming for Equity

In 2020, CEO Albert Bourla laid out a series of goals to demonstrate Pfizer’s dedication to Equity by increasing diversity and inclusion. Here’s the progress that’s been made.

Learn More

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

Our Science
young_woman_getting_vaccinated_380x500_0.png
young_woman_getting_vaccinated_1000x450_0.jpg

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

The U.S. FDA authorization of the Pfizer-BioNTech COVID-19 vaccine for emergency use is a significant step forward in our fight against this pandemic.

Learn More

COMPETITORS WITH A SHARED PURPOSE

Our Purpose
Accumulus_Synergy_790X500_v2.jpg
Accumulus_Synergy_1000X450.jpg

COMPETITORS WITH A SHARED PURPOSE

Accumulus Synergy brings together 10 biopharma companies, including Pfizer, to build a data-sharing platform.

Read On

Search products

Search products, A–Z

Need help paying for Pfizer medicines?

Find a Trial

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Thanking John Young for His Years of Service

Our People
John-Young-Headshot_380X700.png
John-Young-Headshot_1000X450.jpg

Thanking John Young for His Years of Service

Chief Executive Officer Albert Bourla celebrates and thanks Chief Business Officer John Young for his years of service to Pfizer – and to patients.

Read More

PFIZER’S COMMITMENT TO PATIENTS REFLECTED IN NEW IP PACT

Our Purpose
IP-Pact tile image mobile
IP-Pact tile image

PFIZER’S COMMITMENT TO PATIENTS REFLECTED IN NEW IP PACT

Understand the way we use IP and why it matters for what we do.

See how we are living up to that commitment

Latest News

Pfizer Announces Positive Top-Line Results from…

– ALLEGRO 2b/3 trial met primary efficacy endpoint of improving scalp hair regrowth – Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with alopecia areata, an autoimmune disease driven by an immune attack on the hair follicles that causes hair loss on the scalp and can also affect the face and body. 1,2 Ritlecitinib 50 mg and 30 mg achieved the primary efficacy endpoint of the study, namely…
Read more